Morgan Stanley Maintains Equal-Weight on Latham Group, Lowers Price Target to $8
Morgan Stanley analyst Joshua Pokrzywinski maintains Latham Group (NASDAQ:SWIM) with a Equal-Weight and lowers the price target from $12 to $8.
Morgan Stanley Maintains Equal-Weight on Kimco Realty, Lowers Price Target to $22
Morgan Stanley analyst Richard Hill maintains Kimco Realty (NYSE:KIM) with a Equal-Weight and lowers the price target from $25 to $22.
Morgan Stanley Maintains Overweight on Invitation Homes, Lowers Price Target to $40.5
Morgan Stanley analyst Richard Hill maintains Invitation Homes (NYSE:INVH) with a Overweight and lowers the price target from $42.5 to $40.5.
Morgan Stanley Maintains Equal-Weight on Intuitive Surgical, Lowers Price Target to $225
Morgan Stanley analyst Cecilia Furlong maintains Intuitive Surgical (NASDAQ:ISRG) with a Equal-Weight and lowers the price target from $300 to $225.
Morgan Stanley Maintains Overweight on Inari Medical, Lowers Price Target to $93
Morgan Stanley analyst Cecilia Furlong maintains Inari Medical (NASDAQ:NARI) with a Overweight and lowers the price target from $108 to $93.
BMO Capital Maintains Market Perform on Labrador Iron Ore Royalty, Lowers Price Target to C$27.5
BMO Capital analyst Alexander Pearce maintains Labrador Iron Ore Royalty (TSX:LIF) with a Market Perform and lowers the price target from C$35 to C$27.5.
Morgan Stanley Maintains Equal-Weight on Immuneering, Lowers Price Target to $12
Morgan Stanley analyst David Lebowitz maintains Immuneering (NASDAQ:IMRX) with a Equal-Weight and lowers the price target from $18 to $12.
Morgan Stanley Maintains Equal-Weight on Healthpeak Properties, Lowers Price Target to $26
Morgan Stanley analyst Richard Hill maintains Healthpeak Properties (NYSE:PEAK) with a Equal-Weight and lowers the price target from $32.5 to $26.
BMO Capital Maintains Market Perform on Cogeco Communications, Lowers Price Target to C$120
BMO Capital analyst Tim Casey maintains Cogeco Communications (TSX:CCA) with a Market Perform and lowers the price target from C$130 to C$120.
Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $65
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $63 to $65.